Catalyst Pharmaceuticals Executive Cashes Out 10,983 Shares -- What's Behind the Move?

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($23.33).

• What was the quality and operation of this transaction?
  The transaction progressive an workout of 10,983 banal options, which were instantly sold arsenic shares connected the unfastened market. This operation converts vested options into nonstop currency proceeds and reduces nonstop equity vulnerability without expanding underlying stock ownership.

• How important was the disposition comparative to Del Carmen Jeffrey's remaining nonstop holdings?
  The 10,983 shares sold represented astir 73.49% of Del Carmen's nonstop equity holdings anterior to the transaction, materially reducing his nonstop stock number to 3,962 arsenic of November 26, 2025.

• How does this merchantability comparison to anterior insider selling activity?
  In the caller play since August 2024, Del Carmen has completed 3 sales, with a median transaction size of 30,423 shares. The existent merchantability of 10,983 shares is smaller successful implicit terms, but the precocious percent of holdings sold reflects the diminished remaining stock base.

* 1-year terms alteration calculated utilizing Dec. 31, 2025 arsenic the notation date.

• Key products see Firdapse for Lambert-Eaton myasthenic syndrome (LEMS) and Ruzurgi for pediatric LEMS, with pipeline improvement targeting further uncommon neuromuscular and neurological indications.

• The institution operates a commercial-stage biopharmaceutical model, generating gross chiefly from the merchantability of approved therapies for uncommon diseases successful the United States.

• Primary customers are patients with rare, chronic neuromuscular disorders, with organisation channels focused connected specialty healthcare providers and attraction centers.

Catalyst Pharmaceuticals is simply a U.S.-based biotechnology institution specializing successful the improvement and commercialization of therapies for uncommon neuromuscular and neurological diseases.

A apical Catalyst Pharmaceuticals enforcement trimmed his involvement dramatically with this move, selling astir 74% of his nonstop holdings successful an exercise-and-sell transaction.